In a unanimous opinion, the US Supreme Court solidified that inventors lose patent protection for inventions that they had sold or offered to sell more than a year before submitting the patent application - even if those sales were confidential and did not publicize the invention’s details.
The decision in Helsinn Healthcare v Teva provides much needed certainty and continues to incentivize innovation-driven businesses to apply for patents before engaging in sales and marketing activity.
At issue was the scope of the on-sale bar, a part of US patent law since 1836. Before Congress enacted the America Invents Act in 2011, the bar prohibited patenting of an invention “on sale in [the United States] more than one year prior to the date of the application for patent in the United States.”
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze